Safety and Efficacy Study Evaluating Dimebon in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
NCT ID: NCT00829374
Last Updated: 2016-09-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
1003 participants
INTERVENTIONAL
2009-03-31
2011-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease
NCT00838110
A Phase 3 Efficacy Study Of Dimebon In Patients With Moderate To Severe Alzheimer's Disease
NCT00912288
Safety and Tolerability of Dimebon in Patients on Memantine, and Memantine Plus Donepezil
NCT00829816
A Safety and Efficacy Study Evaluating Dimebon (Latrepirdine) in Patients With Moderate to Severe Alzheimer's Disease
NCT00954590
A Safety and Efficacy Study of Oral Dimebon in Patients With Mild-To-Moderate Alzheimer's Disease
NCT00675623
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Dimebon, 5 mg orally three times daily
Dimebon
5 mg orally three times daily
2
Dimebon, 20 mg orally three times daily
Dimebon
20 mg orally three times daily
3
Placebo orally three times daily
Placebo comparator
Placebo orally three times daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dimebon
5 mg orally three times daily
Dimebon
20 mg orally three times daily
Placebo comparator
Placebo orally three times daily
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Probable AD (Diagnostic Statistical Manual of Mental Disorders-IV-Text Revision (DSM-IV-TR))
* Mini-Mental State Examination (MMSE) score between 12 and 24, inclusive
* Stable on donepezil for at least 6 months
Exclusion Criteria
* Major structural brain disease
* Unstable medical condition or significant hepatic or renal disease
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Medivation, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Phoenix, Arizona, United States
Sun City, Arizona, United States
Tucson, Arizona, United States
Costa Mesa, California, United States
Encino, California, United States
Escondido, California, United States
Fresno, California, United States
Garden Grove, California, United States
La Jolla, California, United States
Los Alamitos, California, United States
Los Angeles, California, United States
Martinez, California, United States
Newport, California, United States
Paramount, California, United States
Pasadena, California, United States
San Diego, California, United States
San Francisco, California, United States
Boulder, Colorado, United States
Denver, Colorado, United States
New Haven, Connecticut, United States
Washington D.C., District of Columbia, United States
Deerfield Beach, Florida, United States
Delray Beach, Florida, United States
Jacksonville, Florida, United States
Miami, Florida, United States
Orlando, Florida, United States
Atlanta, Georgia, United States
Honolulu, Hawaii, United States
Indianapolis, Indiana, United States
Lexington, Kentucky, United States
Eaton, Maryland, United States
Boston, Massachusetts, United States
Ann Arbor, Michigan, United States
Las Vegas, Nevada, United States
Mount Arlington, New Jersey, United States
Princeton, New Jersey, United States
Albany, New York, United States
Cedarhurst, New York, United States
New York, New York, United States
Rochester, New York, United States
Durham, North Carolina, United States
Beachwood, Ohio, United States
Toledo, Ohio, United States
Jenkintown, Pennsylvania, United States
Norristown, Pennsylvania, United States
Providence, Rhode Island, United States
Austin, Texas, United States
Houston, Texas, United States
San Antonio, Texas, United States
Charlottesville, Virginia, United States
Seattle, Washington, United States
Middleton, Wisconsin, United States
Newcastle, New South Wales, Australia
Sydney, New South Wales, Australia
Brisbane, Queensland, Australia
Adelaide, South Australia, Australia
Geelong, Victoria, Australia
Melbourne, Victoria, Australia
Perth, Western Australia, Australia
Antwerp, , Belgium
Leuven, , Belgium
Sint-Truiden, , Belgium
Kuppio, , Finland
Oulu, , Finland
Turku, , Finland
Bordeaux, , France
Concert, , France
Lille, , France
Montpellier, , France
Nice, , France
Toulouse, , France
Berlin, , Germany
Bochum, , Germany
Freiburg im Breisgau, , Germany
Hattingen, , Germany
Mannheim, , Germany
Munich, , Germany
Brescia, , Italy
Florence, , Italy
Genoa, , Italy
Perugia, , Italy
Rome, , Italy
Christchurch, Canterbury, New Zealand
Auckland, , New Zealand
Malmo, , Sweden
Norrköping, , Sweden
Stockholm, , Sweden
Brentford, Middlesex, United Kingdom
Rushden, Northhamptonshire, United Kingdom
Glasgow, Scotland, United Kingdom
Worthington, West Sussex, United Kingdom
Bath, , United Kingdom
Blackpool, , United Kingdom
Bradford, , United Kingdom
Greater Manchester, , United Kingdom
London, , United Kingdom
Newcastle upon Tyne, , United Kingdom
Norfolk, , United Kingdom
Oxford, , United Kingdom
Southampton, , United Kingdom
Swindon, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DIM18
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.